Cipla to Market MSD’s Raltegravir in India

by Kathy Jones on  February 21, 2014 at 8:56 PM Indian Health News
RSS Email Print This Page Comment
Font : A-A+

Mumbai-based pharmaceutical company Cipla announced that it has entered into an India-specific strategic partnership with Merck's Indian unit, MSD Pharma, to market the company's anti-HIV drug raltegravir in the country.
 Cipla to Market MSD’s Raltegravir in India
Cipla to Market MSD’s Raltegravir in India

Raltegravir is currently being marketed by MSD in India under the brand name Isentress for treating HIV-1 infection in adult patients. According to the agreement, Cipla will have a non-exclusive license to market, promote and distribute the drug in 400mg strength under a different brand name.

Cipla revealed that it has yet to arrive at a price for the drug, though it is confident that its extensive marketing operations and expertise in HIV/AIDS segment will help it to promote the drug's availability in the country.

"This partnership reinforces Cipla's ongoing commitment to HIV/AIDS treatment making life-saving drugs accessible. Raltegravir, a third line therapy treatment, will be a value-addition to Cipla's portfolio of HIV/AIDS treatment, especially for those patients who are resistant to the first and second line therapy treatment,", the chief medical officer at Cipla, Jaideep Gogtay said.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive